EURETINA 2024

I am a healthcare professional

Notice

Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.

Cookies

We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.

I am a healthcare professional in the United States

Required field.

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

Medical Materials

Agenda

Coming soon

06:00 AM

Duration 4mins Audio-Narrated Free Paper Session

Early Fluid Resolution in the Head-to-Head Phase of the TENAYA/LUCERNE Trials Is Associated With Short- and Long-Term Extended Durability in Patients With Neovascular Age-Related Macular Degeneration Treated With Faricimab▼

Gallego-Pinazo R, Amador M, Dagincourt N, Stoilov I, Margaron P

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 4mins Audio-Narrated Free Paper Session

Assessment of the Clinical Effects of Anti-Ang-2 With Faricimab▼ Based on Key Outcomes From the YOSEMITE/RHINE Trials and Real-World FARETINA/FARWIDE Studies in Patients With DME

Finger R, Manoharan N, Kim J, Amador M, Willis J,Stoilov I, Mar F, Gibson K, Abreu F, Tabano D, Chi G

Ophthalmology | Diabetic Macular Edema

Duration 4mins Audio-Narrated Free Paper Session

Comparison of the Relative Effectiveness of Faricimab▼ vs Aflibercept 8 mg in Diabetic Macular Edema (DME)

Keane P, Holekamp N, Leng T, Siedlecki J, Mar F, Gibson K, Margaron P, Paulo T, Buehrer C, Tabano D

Ophthalmology | Diabetic Macular Edema

Duration 4mins Audio-Narrated Free Paper Session

Intravitreal Interleukin-6 Inhibition With Vamikibart in Uveitic Macular Edema: Final Results From the Phase 1 DOVETAIL Study

Pavesio C, Suhler E, Lin P, Pauly-Evers M, Willen D, Holmes W, Storti F, Barekati Z, Gott T, Passemard B, Macgregor L, Sharma S, Fauser S, Mesquida M

Ophthalmology | Uveitis

Duration 4mins Audio-Narrated Free Paper Session

Patient Preference for the Port Delivery System With Ranibizumab vs Intravitreal Injections: Results From the Phase 3 Pagoda Trial in Patients With Diabetic Macular Edema

Chang M, Koh A, Marcus D, Boldonado K, Daly A, Hill L, Menezes A, Prager A, Wallenstein G, Tian K

Ophthalmology | Diabetic Macular Edema

Duration 4mins Audio-Narrated Free Paper Session

Port Delivery System (PDS) for Continuous Treatment of Diabetic Macular Edema (DME): 2-Year Data From the Phase 3 Pagoda Trial

Graff J, Awh C, Regillo C, Bobbala A, Dakouras A, Howard D, Gune S, Menezes A, Rabena M

Ophthalmology | Diabetic Macular Edema

Duration 4mins Audio-Narrated Free Paper Session

Real-World Treatment Patterns and Visual Outcomes of Faricimab▼ Use Among Eyes With Neovascular Age-Related Macular Degeneration (nAMD) in the United Kingdom: 1 Year Results From the FARWIDE-nAMD Study

McKibbin M, Talks J, DeSalvo G, Patel P, de Silva S, Gale R, Varma D, Dayal P, James N, Shah N, Downey A, Dodds M, Chi G

Ophthalmology | Neovascular Age Related Macular Degeneration

Duration 4mins Audio-Narrated Free Paper Session

Reduction in Pigment Epithelial Detachment With Faricimab▼ vs Aflibercept: A Subgroup Analysis of Patients with Large and Serous PEDs From the Pooled Phase 3 TENAYA and LUCERNE trials

Khanani A, Ambresin A, Avery R, Chaikitmongkol V, Eter N, Gomi F, Lai T, Lim J, London N, Harrell E, Margaron P, Patel S, Souverain A, Yang M

Ophthalmology | Neovascular Age Related Macular Degeneration

09:05 AM

Duration 5mins Speakers Corner

Characterisation of Fibrosis in the Archway Trial: The Impact of Continuous Delivery of Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration

Chakravarthy U, Holekamp N, Blotner S, Cavichini M, Garcia Armendariz B, Kanku M, Heinrich D

Ophthalmology | Age Related Macular Degeneration

09:36 AM

Duration 5mins Room: 118 / 119

Technical Updates to Port Delivery System With Ranibizumab (PDS) for the Treatment of Neovascular Age-related macular degeneration (nAMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR)

Chang M, Pieramici D, Pearce I, Campochiaro P, Holekamp N, Gune S, Quezada Ruiz C, Singh N, Wise G, Ranade S, Horvath J, Regillo C

Ophthalmology | Age Related Macular Degeneration

10:42 AM

Duration 5mins Room: 118 / 119

Faricimab▼ in DME: Results from the RHONE-X Long-Term Extension Trial

Schlottmann P, Khanani A, Lai T, Kotecha A, Sim D, Harrell E, Abreu F, Tang Y, Willis J

Ophthalmology | Diabetic Macular Edema

01:18 PM

Duration 5mins Room: 118 / 119

12-Month Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Patients With Neovascular Age-Related Macular Degeneration: FARETINA-AMD

Lim J, Tabano D, Ali F, Ko S, Borkar D, Leng T, Myrick A, Shaia J, Singh R

Ophthalmology | Age Related Macular Degeneration

01:30 PM

Duration 5mins Speakers Corner

12-Month Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Patients With Diabetic Macular Edema: The FARETINA-DME Study

Sheth V, Tabano D, Ali F, Ko S, Borkar D, Leng T, Myrick A, Shaia J, Singh R

Ophthalmology | Diabetic Macular Edema

07:00 AM

Duration 5mins Room: 118 / 119

Impact of Early Intraretinal Fluid Reduction on Two-Year Outcomes in Diabetic Macular Edema

Lim J, Wang Y, Hibar D, Maunz A, Lu H, Albrecht T, Gibson K, Willis J, Chang D, Litts K

Ophthalmology | Diabetic Macular Edema

07:12 AM

Duration 5mins Room: 118 / 119

Real-World Treatment Patterns and Visual Outcomes of Faricimab▼ Use Among Eyes With Diabetic Macular Edema (DME) in the United Kingdom: 1-Year Results From the FARWIDE-DME Study

Peto T, Sivaprasad S, Reynolds R, Bailey C, Downey L, Kiire C, Pearce I, Dayal P, James N, Shah N, Downey A, Dodds M, Chi G

Ophthalmology | Diabetic Macular Edema

07:18 AM

Duration 5mins Room: 118 / 119

Visual Acuity and Anatomic Improvements at Week 24 Were Maintained Through Week 72 With Faricimab▼ Treat-and-Extend Dosing in the Phase 3 BALATON and COMINO RVO Trials: Patient Case Profiles and Results Summary

Dinah C, Abreu F, Arrisi P, Kotecha A, Liu Y, Paris L, Retiere A, Willis J

Ophthalmology | Retinal Vein Occlusion

07:50 AM

Duration 5mins Speakers Corner

Port Delivery System With Ranibizumab for Continuous Treatment in Diabetic Retinopathy: 2-Year Data From the Phase 3 Pavilion Trial

Khanani A, Chang M, Holmes W, Santhanakrishnan A, Tian K, Wetzel-Smith M, Latkany P

Ophthalmology | Diabetic Macular Edema

09:00 AM

Duration 5mins Room: 118 / 119

Analysis of Extended Interval Treatment Outcomes, Potential for Q20W Dosing and Predictors of Treatment Durability in nAMD With Faricimab▼ From the TENAYA/LUCERNE Trials

Koh A, Ambresin A, Patel P, Singer M, Dagincourt N, Hill L, Kotecha A, Margaron P

Ophthalmology | Neovascular Age Related Macular Degeneration

09:06 AM

Duration 5mins Room: 118 / 119

Key Clinical Outcomes With Faricimab▼ in Treatment-naïve Patients With nAMD: Results From the TENAYA/LUCERNE Trials and Real-World FARETINA/FARWIDE Studies

Souied E, Avery R, Haug S, Tabano D, Chi G, Amador M, Kotecha A, Margaron P, Yang M

Ophthalmology | Neovascular Age Related Macular Degeneration

09:54 AM

Duration 5mins Room: 118 / 119

The Clinical Impact of Continuous Delivery of Ranibizumab With the Port Delivery System (PDS) in Neovascular Age-Related Macular Degeneration (nAMD)

Zinkernagel M, Rachitskaya A, Holekamp N, Dauletbekov D, Blotner S, Heinrich D

Ophthalmology | Age Related Macular Degeneration

10:20 AM

Duration 5mins Grand Auditorium

Global Real-World Clinical and Anatomical Outcomes With Faricimab▼ in Treatment-Naïve Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema From a Multi-Country Prospective Non-Interventional Study: The VOYAGER Study

Bailey C, Chaikitmongkol V, Chaudhary V, Chi G, Downey A, Finger R, Gallego-Pinazo R, Koh A, Ishida S, Lövestam-Adrian M, Parravano M, Luna Pinto J, Schmitz-Valckenberg S, Sheth V, Shi B, Souied E, Uschner D, Guymer R

Ophthalmology | Neovascular Age Related Macular Degeneration

03:00 PM

Duration 5mins Room: 111

Efficacy and Safety of Faricimab▼ in ALTIMETER: A Phase 2b Trial Exploring Biomarkers of Angiopoietin-2 Inhibition in Patients With Diabetic Macular Edema

Ziemssen F, Amador M, Dieckmann A, Gibson K, Glittenberg C, Kotak A, Mar F, Souverain A, Titz B, Vujosevic S, Fawzi A

Ophthalmology | Diabetic Macular Edema

03:06 PM

Duration 5mins Room: 111

Greater Reduction in Hard Exudates With Faricimab▼ vs Aflibercept in Patients With DME: Biomarker Results From the Phase 3 YOSEMITE/RHINE Trials

Dinah C, Vujosevic S, Goldberg R, Ip M, Rahimy E, Amador M, Gibson K, Glittenberg C, Maunz A, O'Leary O, Uschner D

Ophthalmology | Diabetic Macular Edema

03:12 PM

Duration 5mins Room: 111

Predictors of Extended Treatment Intervals in Patients With DME Treated With Faricimab▼ in the Phase 3 YOSEMITE/RHINE Trials

Ambresin A, Gibson K, Sim D, Hill L

Ophthalmology | Diabetic Macular Edema

02:06 PM

Duration 5mins Room: 118 / 119

IL-6 inhibition with vamikibart in patients with uveitic macular edema: phase 3 MEERKAT and SANDCAT trials

Fonollosa A, Suhler E, Steeples L, Elze M, Macgregor L, Silverman D, Haskova Z

Ophthalmology | Uveitis

I am a healthcare professional

Notice

Cookies

External site

EURETINA 2024